|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Founder Mutations for Early Onset Melanoma as Revealed by Whole Exome Sequencing Suggests That This is Not Associated with the Increasing Incidence of Melanoma in Poland
Tadeusz Dębniak, Rodney J Scott, Rodney A Lea, Bohdan Górski, Bartłomiej Masojć, Cezary Cybulski, Andrzej Kram, Romuald Maleszka, Tomasz Gromowski, Katarzyna Paszkowska-Szczur, Aniruddh Kashyap, Marcin R. Lener, Karolina Malińska, Emilia Rogoża, Dawid Murawa, Helena Rudnicka, Jakub Deptuła, Jan Lubiński
Cancer Res Treat.
2019;51(1):337-344. Published online May 14, 2018 DOI:
https://doi.org/10.4143/crt.2018.157
Web of Science 6
Crossref 7
The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
Marcin R. Lener, Aniruddh Kashyap, Wojciech Kluźniak, Cezary Cybulski, Agnieszka Soluch, Sandra Pietrzak, Tomasz Huzarski, Jacek Gronwald, Jan Lubiński
Cancer Res Treat.
2017;49(2):430-436. Published online July 28, 2016 DOI:
https://doi.org/10.4143/crt.2016.217
Web of Science 17
Crossref 17
Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer
Marcin R. Lener, Rodney J. Scott, Anna Wiechowska-Kozłowska, Pablo Serrano-Fernández, Piotr Baszuk, Katarzyna Jaworska-Bieniek, Grzegorz Sukiennicki, Wojciech Marciniak, Magdalena Muszyńska, Józef Kładny, Tomasz Gromowski, Katarzyna Kaczmarek, Anna Jakubowska, Jan Lubiński
Cancer Res Treat.
2016;48(3):1056-1064. Published online December 28, 2015 DOI:
https://doi.org/10.4143/crt.2015.282
Web of Science 65
Crossref 65
1
Journal Impact Factor 4.6